Active Ingredient History

  • Now
Rufinamide is an anti-epileptic drug that is FDA approved for the treatment of lennox-gastaut syndrome (LGS). The principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Hormonal contraceptives may be less effective with rufinamide. Patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults). Common adverse reactions include headache, dizziness, fatigue, somnolence, and nausea.   NCATS

  • Mol. Mass: 238.1935
  • ALogP: 0.7
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$2.3070 - $1377.2500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide | 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- | 60231/4 | banzel | cgp 33101 | cgp-33101 | e2080 | inovelon | ruf-331 | rufinamide | syn111 | xilep


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue